Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Aug;95(8):1241-3.
doi: 10.3324/haematol.2010.025627.

Front-line treatment of mantle cell lymphoma

Christian H Geisler
Editorial

Front-line treatment of mantle cell lymphoma

Christian H Geisler. Haematologica. 2010 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival of the Nordic MCL-2 patients according to the Mantle Cell Lymphoma International Prognostic Index (MIPI). Reproduced with permission of the American Society of Hematology.
See this image and copyright information in PMC

Comment on

References

    1. Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, et al. for the French GOELAMS group. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed Mantle Cell Lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010 Mar 10; [Epub ahead of print] PubMed PMID: 20220059. - PMC - PubMed
    1. Meusers P, Engelhard M, Bartels H, Binder T, Fülle HH, Görg K, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol. 1989;7(5):365–80. - PubMed
    1. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511–8. - PubMed
    1. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11(8):1573–82. - PubMed
    1. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013–23. - PubMed

MeSH terms